Barclays
PBLS

Barclays’s Parabilis Medicines Inc PBLS Stock Holding History

Barclays’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$498K Buy
+15,424
New +$538K ﹤0.01% 3469

Other funds holding PBLS

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Matisse Capital
Matisse Capital Portland, Oregon $256M AUM 15.28% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Barclays's PBLS Position: Q3 2026 in Review

Barclays opened a new position in Parabilis Medicines Inc (PBLS) in Q3 2026: 15,424 shares worth $498K. The stake represents ﹤0.01% of the portfolio and ranks #3469 among its holdings.

35 funds tracked by Wall St. Rank hold PBLS as of Q3 2026.

  • Barclays held 15,424 shares of Parabilis Medicines Inc worth $498K as of Q3 2026.
  • Parabilis Medicines Inc was a new Barclays position in Q3 2026.
  • Parabilis Medicines Inc made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3469 holding.
  • 35 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.